F‑box/WD‑40 repeat‑containing protein 7: A potential target in the progression and treatment of gastrointestinal malignancy (Review)
- Authors:
- Yizhi Wang
- Yang An
- Yi Ma
- Junchao Guo
-
Affiliations: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China, Department of Anesthesia, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Thoracic Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China - Published online on: February 13, 2019 https://doi.org/10.3892/ol.2019.10036
- Pages: 3625-3634
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tsoi KK, Hirai HW, Chan FC, Griffiths S and Sung JJ: Cancer burden with ageing population in urban regions in China: Projection on cancer registry data from World Health Organization. Br Med Bull. 121:83–94. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM and Wender RC: Screening for colorectal cancer and evolving issues for physicians and patients: A review. JAMA. 316:2135–2145. 2016. View Article : Google Scholar : PubMed/NCBI | |
Arkan MC: Cancer: Fat and the fate of pancreatic tumours. Nature. 536:157–158. 2016. View Article : Google Scholar : PubMed/NCBI | |
Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic cancer: Current research status and clinical implications. Angiogenesis. Aug 24–2018.(Epub ahead of print). | |
Xu W, Taranets L and Popov N: Regulating Fbw7 on the road to cancer. Semin Cancer Biol. 36:62–70. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cao J, Ge MH and Ling ZQ: Fbxw7 tumor suppressor: A vital regulator contributes to human tumorigenesis. Medicine (Baltimore). 95:e24962016. View Article : Google Scholar : PubMed/NCBI | |
Davis RJ, Welcker M and Clurman BE: Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shimizu K, Nihira NT, Inuzuka H and Wei W: Physiological functions of FBW7 in cancer and metabolism. Cell Signal. 46:15–22. 2018. View Article : Google Scholar : PubMed/NCBI | |
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI | |
Davis MA, Larimore EA, Fissel BM, Swanger J, Taatjes DJ and Clurman BE: The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator. Genes Dev. 27:151–156. 2013. View Article : Google Scholar : PubMed/NCBI | |
Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR and Sterneck E: FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4. Nat Commun. 4:16622013. View Article : Google Scholar : PubMed/NCBI | |
Bengoechea-Alonso MT and Ericsson J: Tumor suppressor Fbxw7 regulates TGFβ signaling by targeting TGIF1 for degradation. Oncogene. 29:5322–5328. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hao B, Oehlmann S, Sowa ME, Harper JW and Pavletich NP: Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell. 26:131–143. 2007. View Article : Google Scholar : PubMed/NCBI | |
Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, et al: A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife. 2:e008222013. View Article : Google Scholar : PubMed/NCBI | |
Wang L, Ye X, Liu Y, Wei W and Wang Z: Aberrant regulation of FBW7 in cancer. Oncotarget. 5:2000–2015. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kimura T, Gotoh M, Nakamura Y and Arakawa H: hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI | |
Ekholm-Reed S, Goldberg MS, Schlossmacher MG and Reed SI: Parkin-dependent degradation of the F-box protein Fbw7b promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol Cell Biol. 33:3627–3643. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI | |
Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O: Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 12:R1052010. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI | |
Xu Y, Sengupta T, Kukreja L and Minella AC: MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI | |
Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, et al: Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med. 15:2164–2175. 2010. View Article : Google Scholar | |
Cheng X, Hao Y, Shu W, Zhao M, Zhao C, Wu Y, Peng X, Yao P, Xiao D, Qing G, et al: Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis. J Biol Chem. 292:9022–9033. 2017. View Article : Google Scholar : PubMed/NCBI | |
Schülein-Völk C, Wolf E, Zhu J, Xu W, Taranets L, Hellmann A, Jänicke LA, Diefenbacher ME, Behrens A, Eilers M, et al: Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell Rep. 9:1099–1109. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sancho R, Blake SM, Tendeng C, Clurman BE, Lewis J and Behrens A: Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 11:e10015862013. View Article : Google Scholar : PubMed/NCBI | |
Tong J, Tan S, Zou F, Yu J and Zhang L: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 36:787–796. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gong J, Zhou Y, Liu D and Huo J: F-box proteins involved in cancer-associated drug resistance. Oncol Lett. 15:8891–8900. 2018.PubMed/NCBI | |
Suryo Rahmanto A, Swartling FJ and Sangfelt O: Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence. Mol Cell Oncol. 4:e12528712016. View Article : Google Scholar : PubMed/NCBI | |
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004. View Article : Google Scholar : PubMed/NCBI | |
Biswas M, Phan D, Watanabe M and Chan JY: The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysis. J Biol Chem. 286:39282–39289. 2011. View Article : Google Scholar : PubMed/NCBI | |
Welcker M, Larimore EA, Frappier L and Clurman BE: Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol. 31:1214–1224. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle. 10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H: Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li J, Guo Y, Liang X, Sun M, Wang G, De W and Wu W: MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 138:763–774. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ma J, Cheng L, Liu H, Zhang J, Shi Y, Zeng F, Miele L, Sarkar FH, Xia J and Wang Z: Genistein down-regulates miR-223 expression in pancreatic cancer cells. Curr Drug Targets. 14:1150–1156. 2013. View Article : Google Scholar : PubMed/NCBI | |
Takada M, Zhang W, Suzuki A, Kuroda TS, Yu Z, Inuzuka H, Gao D, Wan L, Zhuang M, Hu L, et al: FBW7 loss promotes chromosomal instability and tumorigenesis via Cyclin E1/CDK2-mediated phosphorylation of CENP-A. Cancer Res. 77:4881–4893. 2017.PubMed/NCBI | |
Li Y, Hu K, Xiao X, Wu W, Yan H, Chen H, Chen Z and Yin D: FBW7 suppresses cell proliferation and G2/M cell cycle transition via promoting γ-catenin K63-linked ubiquitylation. Biochem Biophys Res Commun. 497:473–479. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng L, Shi Y, Wang H, Yin B, Xia J and Wang Z: Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Liu H, Hou Y, Zhou X, Liang L, Zhang Z, Shi H, Xu S, Hu P, Zheng Z, et al: Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. Virchows Arch. 472:959–968. 2018. View Article : Google Scholar : PubMed/NCBI | |
Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H and Mori M: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int J Cancer. 126:1828–1837. 2010. View Article : Google Scholar : PubMed/NCBI | |
Li Q, Li Y, Li J, Ma Y, Dai W, Mo S, Xu Y, Li X and Cai S: FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis. Int J Biol Sci. 14:726–735. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ou B, Zhao J, Guan S, Wangpu X, Zhu C, Zong Y, Ma J, Sun J, Zheng M, Feng H and Lu A: Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer. Cancer Lett. 380:457–466. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cizmecioglu O, Krause A, Bahtz R, Ehret L, Malek N and Hoffmann I: Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4). J Cell Sci. 125:981–992. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jung JH, Jung DB, Kim H, Lee H, Kang SE, Srivastava SK, Yun M and Kim SH: Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7. Oncogene. 37:3715–3728. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li L, Sarver AL, Khatri R, Hajeri PB, Kamenev I, French AJ, Thibodeau SN, Steer CJ and Subramanian S: Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. J Pathol. 234:488–501. 2014. View Article : Google Scholar : PubMed/NCBI | |
Khan OM, Carvalho J, Spencer-Dene B, Mitter R, Frith D, Snijders AP, Wood SA and Behrens A: The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. J Clin Invest. 128:1326–1337. 2018. View Article : Google Scholar : PubMed/NCBI | |
Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J and Lee MH: Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Mol Cancer Ther. 14:1476–1487. 2015. View Article : Google Scholar : PubMed/NCBI | |
Imura S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, et al: The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol. 29:1822–1829. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Zhang J, Zhou L, Sun W, Zheng ZG, Lu P, Gao Y, Yang XS, Zhang ZC, Tao KS and Dou KF: Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. Int J Oncol. 47:231–243. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Wang H, Wang J, Huang S and Zhang W: STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. Cancer Cell Int. 15:1112015. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C, Dou C, Xu M, Liu Q and Tu K: Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 16:1232017. View Article : Google Scholar : PubMed/NCBI | |
Yu J, Zhang W, Gao F, Liu YX, Chen ZY, Cheng LY, Xie SF and Zheng SS: FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int. 13:184–191. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, et al: Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget. 8:29771–29784. 2017.PubMed/NCBI | |
Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer. 42:2369–2373. 2006. View Article : Google Scholar : PubMed/NCBI | |
Jiang Y, Qi X, Liu X, Zhang J, Ji J, Zhu Z, Ren J and Yu Y: Fbxw7 haploinsufficiency loses its protection against DNA damage and accelerates MNU-induced gastric carcinogenesis. Oncotarget. 8:33444–33456. 2017.PubMed/NCBI | |
Li MR, Zhu CC, Ling TL, Zhang YQ, Xu J, Zhao EH and Zhao G: FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma. BMC Gastroenterol. 17:602017. View Article : Google Scholar : PubMed/NCBI | |
Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M: p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li H, Wang Z, Zhang W, Qian K, Xu W and Zhang S: Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer. Cancer Lett. 370:39–55. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhou X, Jin W, Jia H, Yan J and Zhang G: MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI | |
Eto K, Iwatsuki M, Watanabe M, Ishimoto T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al: The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015. View Article : Google Scholar : PubMed/NCBI | |
Naganawa Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Tanaka T, Shiozaki M, Fujii Y and Takeyama H: Decreased expression of FBXW7 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Exp Ther Med. 1:841–846. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yokobori T, Mimori K, Iwatsuki M, Ishii H, Tanaka F, Sato T, Toh H, Sudo T, Iwaya T, Tanaka Y, et al: Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma. Int J Oncol. 41:253–259. 2012.PubMed/NCBI | |
Er TK, Wang YY, Chen CC, Herreros-Villanueva M, Liu TC and Yuan SS: Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing. Oral Dis. 21:872–878. 2015. View Article : Google Scholar : PubMed/NCBI | |
Arita H, Nagata M, Yoshida R, Matsuoka Y, Hirosue A, Kawahara K, Sakata J, Nakashima H, Kojima T, Toya R, et al: FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study. Tumour Biol. Oct 26–2017.(Epub ahead of print). doi: 1010428317731771, 2017. View Article : Google Scholar : PubMed/NCBI | |
Hua Y, Zhao K, Tao G, Dai C and Su Y: miR-25 promotes metastasis via targeting FBXW7 in esophageal squamous cell carcinoma. Oncol Rep. 38:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI | |
Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH and Kern SE: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. Am J Pathol. 163:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI | |
Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB and Mohammad RM: Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget. 5:3444–3454. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jiang JX, Sun CY, Tian S, Yu C, Chen MY and Zhang H: Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer. Tumour Biol. 37:13893–13902. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ji S, Qin Y, Liang C, Huang R, Shi S, Liu J, Jin K, Liang D, Xu W, Zhang B, et al: FBW7 (F-box and WD Repeat Domain-Containing 7) negatively regulates glucose metabolism by targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) axis in pancreatic cancer. Clin Cancer Res. 22:3950–3960. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hu Q, Qin Y, Zhang B, Liang C, Ji S, Shi S, Xu W, Xiang J, Liang D, Ni Q, et al: FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncol Rep. 38:2069–2077. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 25:561–573. 2015. View Article : Google Scholar : PubMed/NCBI | |
He D, Huang C, Zhou Q, Liu D, Xiong L, Xiang H, Ma G and Zhang Z: HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion. Oncotarget. 8:20165–20178. 2017.PubMed/NCBI | |
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. Asian Pac J Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ye M, Zhang Y, Zhang X and Zhang J, Jing P, Cao L, Li N, Li X, Yao L and Zhang J and Zhang J: Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res. 77:3527–3539. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lin J, Ji A, Qiu G, Feng H, Li J, Li S, Zou Y, Cui Y, Song C, He H and Lu Y: FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. Cancer Sci. 109:1001–1011. 2018. View Article : Google Scholar : PubMed/NCBI | |
Takada M, Zhuang M, Inuzuka H, Zhang J, Zurlo G, Zhang J and Zhang Q: EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. Oncotarget. 8:6787–6795. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yao S, Xu F, Chen Y, Ge Y, Zhang F, Huang H, Li L, Lin D, Luo X, Xu J, et al: Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. J Exp Clin Cancer Res. 36:102017. View Article : Google Scholar : PubMed/NCBI | |
Liang Y, Dong B, Shen J, Ma C and Ma Z: Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer. Oncol Lett. 17:849–856. 2019.PubMed/NCBI | |
Niu W, Luo Y, Wang X, Zhou Y, Li H, Wang H, Fu Y, Liu S, Yin S, Li J, et al: BRD7 inhibits the Warburg effect and tumor progression through inactivation of HIF1α/LDHA axis in breast cancer. Cell Death Dis. 9:5192018. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W, Zhou Y, Qiu Y, Fan S, Zhan Y, et al: BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141. J Exp Clin Cancer Res. 37:642018. View Article : Google Scholar : PubMed/NCBI | |
Yu X, Li Z and Shen J: BRD7: A novel tumor suppressor gene in different cancers. Am J Transl Res. 8:742–748. 2016.PubMed/NCBI | |
Jin X, Yang C, Fan P, Xiao J, Zhang W, Zhan S, Liu T, Wang D and Wu H: CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. J Biol Chem. 292:6269–6280. 2017. View Article : Google Scholar : PubMed/NCBI | |
Arabi A, Ullah K, Branca RM, Johansson J, Bandarra D, Haneklaus M, Fu J, Ariës I, Nilsson P, Den Boer ML, et al: Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. Nat Commun. 3:9762012. View Article : Google Scholar : PubMed/NCBI | |
Zeligs KP, Neuman MK and Annunziata CM: Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear Factor-κB signaling for cancer treatment. Clin Cancer Res. 22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chang CC, Lin HH, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Chen WS, Lin TC, Jiang JK and Chang SC: FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients. Int J Biol Markers. 30:e88–e95. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tu K, Zheng X, Zan X, Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI | |
Enkhbold C, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Ishikawa D and Shimada M: Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Hepatol Res. 44:E346–E352. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ishii N, Araki K, Yokobori T, Gantumur D, Yamanaka T, Altan B, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, et al: Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Oncotarget. 8:112636–112646. 2017. View Article : Google Scholar : PubMed/NCBI |